ISPOR, the largest annual health-economic conference, held at the beginning of November gathered decision-makers, pharmaceutical industry, clinical research organisations and consultancy companies together. This year’s conference focused on medicines evaluation and health technology assessment.
- It seemed to be the general opinion that evaluations and assessments should be made more and more in co-operation between the authorities from different countries, states our Regulatory and Market Access expert Hanne Juuti.
Co-operation can produce high-quality and topical scientific reports, transparent processes and clear requirements for the evidence required.
New cell and gene therapies challenge the basic hypotheses in health-economic models
Availability of new innovative medicines and other health technologies increases; this highlights the significance of decision-making when introduction of new technologies and their costs are considered.
- Information is thus needed to support decision-making to allow balancing between the payer’s budget and patients’ needs, says our Market Access expert Jarno Kotajärvi.
Topics that emerged in this year’s discussions included new types of cell and gene therapies and how these differ from traditional medicinal products. These discussions concerned particularly the challenges posed by the basic hypotheses in health-economic models, new types of pricing models and value-based pricing.
High-quality registers in the Nordic countries received well-deserved attention
It was brought up in the lectures and lobbying that our high-quality registers encourage companies to include the Nordic countries already in the first wave of product launches. The good-quality data obtained from the Nordic countries is useful for further studies and can also be used outside the Nordic countries.
Interest in using RWE for decision-making is continuously growing
Many sessions in the conference concerned RWD (real-world data) and RWE (real-world evidence). Although the potential of RWE has been recognised, introducing it into the evaluation of new medicines and other health technology assessments has been slow.
- Issues on reliability of data have created challenges related to lack of randomisation, quality of the information and potentially incorrect results caused by data mining, our Health Economics expert Viivi Friman sums up.
DRA’s experts took part in this conference held in Copenhagen among 5,500 other professionals in this field.
[linkbox text=”Do not let the price slow you down; ask for help from our Market Access team.” buttontext=”Contact us” url=#]